ChromaDex Co. (NASDAQ:CDXC) Short Interest Up 6.7% in December

ChromaDex Co. (NASDAQ:CDXC) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 2,070,000 shares, an increase of 6.7% from the December 15th total of 1,940,000 shares. Currently, 4.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is presently 1.6 days.

Analysts Set New Price Targets

CDXC has been the subject of several analyst reports. HC Wainwright raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, November 4th. Roth Mkm raised their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Wednesday, November 6th. Finally, StockNews.com cut ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 15th.

Insider Activity

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the stock in a transaction on Friday, December 13th. The shares were sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the transaction, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This trade represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 9.64% of the company’s stock.

Hedge Funds Weigh In On ChromaDex

A number of large investors have recently added to or reduced their stakes in the company. USA Financial Formulas purchased a new position in shares of ChromaDex in the 4th quarter worth approximately $25,000. The Manufacturers Life Insurance Company purchased a new position in ChromaDex in the second quarter worth $31,000. Merriman Wealth Management LLC acquired a new position in shares of ChromaDex during the second quarter worth $32,000. FMR LLC purchased a new stake in shares of ChromaDex during the 3rd quarter valued at $55,000. Finally, SG Americas Securities LLC acquired a new stake in shares of ChromaDex in the 3rd quarter worth $61,000. 15.41% of the stock is currently owned by institutional investors.

ChromaDex Stock Up 5.1 %

Shares of NASDAQ:CDXC opened at $5.94 on Tuesday. The business’s 50 day moving average is $6.32 and its 200 day moving average is $4.49. The stock has a market cap of $453.72 million, a P/E ratio of 594.59 and a beta of 2.21. ChromaDex has a 52-week low of $1.36 and a 52-week high of $7.97.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.02 EPS for the quarter. The firm had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. During the same quarter last year, the firm posted ($0.01) earnings per share. On average, sell-side analysts anticipate that ChromaDex will post 0.04 EPS for the current fiscal year.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.